{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:09:15Z","timestamp":1793815755928,"version":"4.6.1"},"reference-count":223,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8257156377"],"award-info":[{"award-number":["8257156377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274566"],"award-info":[{"award-number":["82274566"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.intimp.2026.116821","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:13:02Z","timestamp":1778760782000},"page":"116821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["VEGF\/VEGFR targeting-induced vascular normalization: a key strategy to reverse cold tumor phenotype and potentiate immunotherapy in gynecologic cancers"],"prefix":"10.1016","volume":"182","author":[{"given":"Yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjuan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12943-024-02179-5","article-title":"Current trends in sensitizing immune checkpoint inhibitors for cancer treatment","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"7637","key":"10.1016\/j.intimp.2026.116821_bb0015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0020","article-title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","volume":"6","author":"Sacco","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.intimp.2026.116821_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1661545","article-title":"Infiltration characteristics and regulatory mechanisms of CD8(+) T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment","volume":"16","author":"Ouyang","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41587-025-02597-w","article-title":"Turn cold tumors hot by reprogramming the tumor microenvironment","volume":"43","author":"Yuan","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0035","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"issue":"7621","key":"10.1016\/j.intimp.2026.116821_bb0040","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0045","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/ni1102-999","article-title":"Natural selection of tumor variants in the generation of \u201ctumor escape\u201d phenotypes","volume":"3","author":"Khong","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/emm.2002.3","article-title":"Alterations of HLA class I and class II antigen expressions in borderline, invasive and metastatic ovarian cancers","volume":"34","author":"Le","year":"2002","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0055","doi-asserted-by":"crossref","first-page":"8990","DOI":"10.1038\/s41598-018-25583-6","article-title":"Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/2326-6066.CIR-14-0149","article-title":"High and interrelated rates of PD-L1+CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment of metastatic lymph nodes from patients with cervical cancer","volume":"3","author":"Heeren","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0065","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/path.6012","article-title":"The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients","volume":"258","author":"L\u00f3pez-Janeiro","year":"2022","journal-title":"J. Pathol."},{"key":"10.1016\/j.intimp.2026.116821_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1667464","article-title":"Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116821_bb0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2147\/OTT.S537872","article-title":"Crosstalk between immunity and oncogenes within the tumor microenvironment of HPV-associated cervical squamous cell carcinoma","volume":"18","author":"Alahmadi","year":"2025","journal-title":"Onco. Targets Ther."},{"issue":"10","key":"10.1016\/j.intimp.2026.116821_bb0080","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/biom15101370","article-title":"Traditional and new views on MSI-H\/dMMR endometrial Cancer","volume":"15","author":"Liu","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.116821_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2025.100259","article-title":"60eP machine learning-guided integration of transcriptomic data and immune cell fractions identifies immune-hot biomarkers in pMMR endometrial cancer","volume":"10","author":"Matei","year":"2025","journal-title":"ESMO Real World Data and Digital Oncology"},{"key":"10.1016\/j.intimp.2026.116821_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117585","article-title":"Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF\/VEGFR pathway","volume":"180","author":"Lorenc","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0095","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell Death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0100","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0105","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2026.116821_bb0110","article-title":"Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management","volume":"73","author":"da Cunha Colombo Bonadio","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0115","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s00404-024-07504-3","article-title":"Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe","volume":"309","author":"Kelkar","year":"2024","journal-title":"Arch. Gynecol. Obstet."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0120","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e105","article-title":"Prevalence and prognostic value of PD-L1 expression and tumor mutational burden in persistent, recurrent, or metastatic cervical cancer","volume":"35","author":"Baek","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.1992.tb51603.x","article-title":"Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation","volume":"667","author":"Dvorak","year":"1992","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.intimp.2026.116821_bb0130","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1161\/ATVBAHA.125.323060","article-title":"Heparanase 2 modulates vascular permeability via Heparan sulfate-dependent growth factor signaling","volume":"45","author":"Becker","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2026.116821_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122563","article-title":"VEGF\/VEGFR axis and its signaling in melanoma: current knowledge toward therapeutic targeting agents and future perspectives","volume":"345","author":"Malekan","year":"2024","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0145","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011056","article-title":"PlGF: a multitasking cytokine with disease-restricted activity","volume":"2","author":"Dewerchin","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.intimp.2026.116821_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.616837","article-title":"Direct and indirect modulation of T cells by VEGF-A counteracted by anti-Angiogenic treatment","volume":"12","author":"Bourhis","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ags3.12249","article-title":"Cancer-associated fibroblasts show heterogeneous gene expression and induce vascular endothelial growth factor a (VEGFA) in response to environmental stimuli","volume":"3","author":"Inoue","year":"2019","journal-title":"Ann Gastroenterol Surg"},{"issue":"16","key":"10.1016\/j.intimp.2026.116821_bb0160","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1073\/pnas.94.16.8761","article-title":"Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGFwithdrawal","volume":"94","author":"Benjamin","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0165","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41568-024-00745-z","article-title":"Compressive stresses in cancer: characterization and implications for tumour progression and treatment","volume":"24","author":"Linke","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.intimp.2026.116821_bb0170","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1158\/0008-5472.CAN-12-4521","article-title":"Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse","volume":"73","author":"Stylianopoulos","year":"2013","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb0175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/hh1801.097034","article-title":"Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression","volume":"89","author":"Kim","year":"2001","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0185","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.4049\/jimmunol.178.3.1505","article-title":"Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy","volume":"178","author":"Bouzin","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0190","first-page":"1111","article-title":"Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors","volume":"56","author":"Griffioen","year":"1996","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian Cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0200","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116821_bb0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-015-0350-0","article-title":"Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer","volume":"14","author":"Punt","year":"2015","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0210","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/bjc.2012.468","article-title":"VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2","volume":"107","author":"Gavalas","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0215","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ijc.26094","article-title":"VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2","volume":"130","author":"Ziogas","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0220","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","article-title":"Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors","volume":"73","author":"Duraiswamy","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0225","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1007\/s13277-015-3133-8","article-title":"Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients","volume":"36","author":"Wertel","year":"2015","journal-title":"Tumour Biol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0230","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00262-020-02808-0","article-title":"Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients","volume":"70","author":"Kajal","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/MCB.23.1.14-25.2003","article-title":"Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis","volume":"23","author":"Liu","year":"2003","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0240","first-page":"1667","article-title":"VEGF secreted by mesenchymal stem cells mediates the differentiation of endothelial progenitor cells into endothelial cells via paracrine mechanisms","volume":"17","author":"Ge","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0245","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006569","article-title":"VEGF and notch in tip and stalk cell selection","volume":"3","author":"Blanco","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"10","key":"10.1016\/j.intimp.2026.116821_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110451","article-title":"Notch-mediated lactate metabolism regulates MDSC development through the Hes1\/MCT2\/c-Jun axis","volume":"38","author":"Zhao","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116821_bb0255","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2016.08.019","article-title":"The blockage of notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression","volume":"68","author":"Wang","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0260","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/s12967-025-06282-z","article-title":"Notch signaling in the tumor immune microenvironment of colorectal cancer: mechanisms and therapeutic opportunities","volume":"23","author":"Sun","year":"2025","journal-title":"J. Transl. Med."},{"issue":"14","key":"10.1016\/j.intimp.2026.116821_bb0265","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.7150\/thno.44147","article-title":"Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer","volume":"10","author":"Liao","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0270","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12885-023-10526-w","article-title":"Notch3 signaling promotes colorectal tumor growth by enhancing immunosuppressive cells infiltration in the microenvironment","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0664-4","article-title":"Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-\u03b21","volume":"37","author":"Yang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0280","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.4049\/jimmunol.160.3.1224","article-title":"Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells","volume":"160","author":"Oyama","year":"1998","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0285","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0290","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4049\/jimmunol.174.1.215","article-title":"Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation","volume":"174","author":"Dikov","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116821_bb0295","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.phrs.2018.08.023","article-title":"Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors","volume":"136","author":"Lacal","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116821_bb0300","doi-asserted-by":"crossref","unstructured":"Xiong Y, Lingrel JB, W\u00fcthrich M, Klein BS, Vasudevan NT, Jain MK, George M, Deepe GS, Jr. (2016) Transcription factor KLF2 in dendritic cells downregulates Th2 programming via the HIF-1\u03b1\/Jagged2\/Notch Axis. mBio 7 (3). doi:https:\/\/doi.org\/10.1128\/mBio.00436-16.","DOI":"10.1128\/mBio.00436-16"},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0305","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrrheum.2016.147","article-title":"Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles","volume":"12","author":"Coutant","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0310","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","article-title":"Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma","volume":"80","author":"Zhang","year":"2024","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0315","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"6453","key":"10.1016\/j.intimp.2026.116821_bb0320","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0325","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1073\/pnas.1518000113","article-title":"Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1\u03b1-dependent","volume":"113","author":"Liu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01105-4","article-title":"Crosstalk between macrophages and cardiac cells after myocardial infarction","volume":"21","author":"Jian","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0335","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cmet.2017.06.004","article-title":"Similarities and distinctions of Cancer and immune metabolism in inflammation and tumors","volume":"26","author":"Andrejeva","year":"2017","journal-title":"Cell Metab."},{"issue":"30","key":"10.1016\/j.intimp.2026.116821_bb0345","article-title":"Bispecific antibody targeting VEGF\/TGF-\u03b2 synergizes with local radiotherapy: turning tumors from cold to inflamed and amplifying Abscopal effects","volume":"12","author":"Lyu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.intimp.2026.116821_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116427","article-title":"HIF-1\u03b1 mediates immunosuppression and Chemoresistance in colorectal Cancer by inhibiting CXCL9, \u221210 and \u221211","volume":"173","author":"Su","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"16","key":"10.1016\/j.intimp.2026.116821_bb0355","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-15-0204","article-title":"CCL2 and CCL5 are novel therapeutic targets for estrogen-dependent breast Cancer","volume":"21","author":"Svensson","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0360","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1039\/D0NH00588F","article-title":"Tumor-targeted gene therapy with lipid nanoparticles inhibits tumor-associated adipocytes and remodels the immunosuppressive tumor microenvironment in triple-negative breast cancer","volume":"6","author":"Liu","year":"2021","journal-title":"Nanoscale Horiz."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0365","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.virol.2009.02.036","article-title":"Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses","volume":"387","author":"Nakamura","year":"2009","journal-title":"Virology"},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0370","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/bjc.2013.817","article-title":"Increased expression of RRM2 by human papillomavirus E7 oncoprotein promotes angiogenesis in cervical cancer","volume":"110","author":"Wang","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116821_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2022.109449","article-title":"Human papillomavirus 16 E6\/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p\/PD-L1 axis","volume":"731","author":"Ling","year":"2022","journal-title":"Arch. Biochem. Biophys."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0380","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb0385","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0753-3322(99)80122-X","article-title":"HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes","volume":"53","author":"Le Buanec","year":"1999","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0390","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12935-023-03189-x","article-title":"Identification of a new gene signature for prognostic evaluation in cervical cancer: based on cuproptosis-associated angiogenesis and multi-omics analysis","volume":"24","author":"Kang","year":"2024","journal-title":"Cancer Cell Int."},{"issue":"30","key":"10.1016\/j.intimp.2026.116821_bb0395","doi-asserted-by":"crossref","first-page":"29889","DOI":"10.18632\/oncotarget.5092","article-title":"Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model","volume":"6","author":"Gremonprez","year":"2015","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.intimp.2026.116821_bb0400","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.intimp.2026.116821_bb0405","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0410","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102620","article-title":"Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity","volume":"36","author":"Zhang","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0420","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/1078-0432.CCR-23-0771","article-title":"Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian Cancer (GEICO-89T\/MINOVA study)","volume":"30","author":"Tavira","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030380","article-title":"Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian Cancer patients by favoring the recruitment of effector T cell subsets","volume":"8","author":"Napoletano","year":"2019","journal-title":"J. Clin. Med."},{"issue":"Pt B","key":"10.1016\/j.intimp.2026.116821_bb0430","article-title":"Anti-tumour effect of in situ vaccines combined with VEGFR inhibitors in the treatment of metastatic cervical cancer","volume":"101","author":"Liu","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010541","article-title":"Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer","volume":"13","author":"Roudko","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116821_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101665","article-title":"Tregs are involved in VEGFA\/ VASH1-related angiogenesis pathway in ovarian cancer","volume":"32","author":"Qiao","year":"2023","journal-title":"Transl. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0445","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ygyno.2008.04.021","article-title":"The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer","volume":"110","author":"Giatromanolaki","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0450","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0455","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1158\/0008-5472.CAN-07-6705","article-title":"Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice","volume":"68","author":"Dineen","year":"2008","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007669","article-title":"Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer","volume":"4","author":"Roland","year":"2009","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0465","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-08-4709","article-title":"The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies","volume":"69","author":"Ozao-Choy","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0470","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.989764","article-title":"Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication","volume":"4","author":"Draghiciu","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.intimp.2026.116821_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2026.116821_bb0480","article-title":"Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity","author":"Rinchai","year":"2020","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0485","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00262-007-0441-x","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0490","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","article-title":"Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF","volume":"110","author":"Huang","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.intimp.2026.116821_bb0495","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1158\/1078-0432.CCR-08-0656","article-title":"Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival","volume":"14","author":"van Cruijsen","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0500","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0505","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1753425916659702","article-title":"Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells","volume":"22","author":"Zhao","year":"2016","journal-title":"Innate Immun."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128897","article-title":"The VEGF-receptor inhibitor Axitinib impairs dendritic cell phenotype and function","volume":"10","author":"Heine","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0515","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/15200","article-title":"Natural adjuvants: endogenous activators of dendritic cells","volume":"5","author":"Gallucci","year":"1999","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25073933","article-title":"Predicting response to Immunotargeted therapy in endometrial Cancer via tumor immune microenvironment: a multicenter, observational study","volume":"25","author":"Maltseva","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0525","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ijc.70199","article-title":"HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: phase II CENTAURO-4 trial results","volume":"158","author":"Hern\u00e1ndez-Bernal","year":"2026","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0530","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8247","article-title":"Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors","volume":"47","author":"Ishikura","year":"2022","journal-title":"Oncol. Rep."},{"issue":"385","key":"10.1016\/j.intimp.2026.116821_bb0535","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0540","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0545","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s10585-024-10309-y","article-title":"PD-L1 and VEGF dual blockade enhances anti-tumor effect on brain metastasis in hematogenous metastasis model","volume":"41","author":"Masuda","year":"2024","journal-title":"Clin. Exp. Metastasis"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0550","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-023-01487-5","article-title":"Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy","volume":"16","author":"Niu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0555","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.778978","article-title":"A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0560","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0565","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance Durvalumab with or without Olaparib as first-line treatment for advanced endometrial Cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0570","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4251\/wjgo.v15.i1.55","article-title":"Challenges and exploration for immunotherapies targeting cold colorectal cancer","volume":"15","author":"Li","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"issue":"22","key":"10.1016\/j.intimp.2026.116821_bb0575","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of Pembrolizumab in advanced programmed death ligand 1-positive endometrial Cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.intimp.2026.116821_bb0580","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus Pembrolizumab in patients with advanced endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0585","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for advanced endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.intimp.2026.116821_bb0590","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus Pembrolizumab in previously treated advanced endometrial Cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0595","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007929","article-title":"Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from study 111\/KEYNOTE-146","volume":"12","author":"Makker","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0600","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e40","article-title":"Analysis of East Asia subgroup in study 309\/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician\u2019s choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer","volume":"35","author":"Yonemori","year":"2024","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0605","doi-asserted-by":"crossref","unstructured":"Marth C, Moore RG, Bidzi\u0144ski M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V (2025) First-line Lenvatinib plus Pembrolizumab versus chemotherapy for advanced endometrial cancer: a randomized, open-label, phase III trial. J. Clin. Oncol. 43 (9):1083\u20131100. doi:https:\/\/doi.org\/10.1200\/jco-24-01326.","DOI":"10.1200\/JCO-24-01326"},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0610","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008037","article-title":"Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-a bispecific antibody, in patients with advanced solid tumors","volume":"12","author":"Frentzas","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116821_bb0615","doi-asserted-by":"crossref","unstructured":"Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC (2017) Safety and clinical activity of the programmed death-ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor Olaparib or vascular endothelial growth factor receptor 1-3 inhibitor Cediranib in women's cancers: a dose-escalation, phase I study. J. Clin. Oncol. 35 (19):2193\u20132202. doi:https:\/\/doi.org\/10.1200\/jco.2016.72.1340.","DOI":"10.1200\/JCO.2016.72.1340"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0620","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","article-title":"A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses","volume":"7","author":"Zimmer","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.intimp.2026.116821_bb0625","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0630","doi-asserted-by":"crossref","first-page":"358","DOI":"10.20517\/cdr.2023.13","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we go from here?","volume":"6","author":"Yoon","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.intimp.2026.116821_bb0635","doi-asserted-by":"crossref","unstructured":"Grillo E, Romani C, Ettorre VM, Santin AD, Mitola S (2025) The VEGF\/VEGFR2 system in ovarian cancer: from functional to pharmacological significance. Biochim. Biophys. Acta Rev. Cancer 1880 (4):189374. doi:https:\/\/doi.org\/10.1016\/j.bbcan.2025.189374, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.","DOI":"10.1016\/j.bbcan.2025.189374"},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103666","article-title":"PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: dilemmas and opportunities","volume":"28","author":"Peng","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0645","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0650","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2019.12.012","article-title":"Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor","volume":"157","author":"Xue","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0655","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2026.116821_bb0660","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1276694","article-title":"Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer","volume":"14","author":"Yu","year":"2023","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0665","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined Nivolumab and bevacizumab in relapsed ovarian Cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116821_bb0670","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1158\/1078-0432.CCR-24-3368","article-title":"Bevacizumab, Atezolizumab, and acetylsalicylic acid in recurrent, platinum-resistant ovarian Cancer: the EORTC 1508-GCG phase II study","volume":"31","author":"Banerjee","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"17","key":"10.1016\/j.intimp.2026.116821_bb0675","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian Cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0680","doi-asserted-by":"crossref","unstructured":"Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez Garc\u00eda J, Petru E, Koci\u00e1n R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier \u00c9, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F (2023) Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial. J. Clin. Oncol. 41 (30):4768\u20134778. doi:https:\/\/doi.org\/10.1200\/jco.23.00529.","DOI":"10.1200\/JCO.23.00529"},{"issue":"24","key":"10.1016\/j.intimp.2026.116821_bb0685","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0690","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70653","article-title":"Safety, pharmacokinetics, and pharmacodynamics evaluation of Ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF, in Chinese patients with advanced solid tumors","volume":"14","author":"Wang","year":"2025","journal-title":"Cancer Med."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.116821_bb0695","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.2024.42.16_suppl.5524","article-title":"Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts","volume":"42","author":"Wu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0700","series-title":"Phase Ib\/IIa Safety and Efficacy of PM8002, a Bispecific Antibody Targeting PD-L1 and VEGF-A, as a Monotherapy in Patients with Advanced Solid Tumors","author":"Guo","year":"2023"},{"issue":"17_suppl","key":"10.1016\/j.intimp.2026.116821_bb0705","doi-asserted-by":"crossref","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"Harter","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0710","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus Durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian Cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0715","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/1078-0432.CCR-24-3877","article-title":"Comparing Durvalumab, Olaparib, and Cediranib monotherapy, combination therapy, or chemotherapy in patients with platinum-resistant ovarian Cancer with prior bevacizumab: the phase II NRG-GY023 trial","volume":"31","author":"Lee","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.intimp.2026.116821_bb0720","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1200\/JCO.2023.41.16_suppl.2536","article-title":"Phase Ib\/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors","volume":"41","author":"Guo","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0725","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb0730","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/ijgc-2022-003728","article-title":"The increasing incidence of stage IV cervical cancer in the USA: what factors are related?","volume":"32","author":"Francoeur","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.intimp.2026.116821_bb0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156334","article-title":"Immune microenvironment of cervical cancer and the role of IL-2 in tumor promotion","volume":"170","author":"Trujillo-Cirilo","year":"2023","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0740","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron."},{"issue":"18","key":"10.1016\/j.intimp.2026.116821_bb0745","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","article-title":"Cervical Cancer immunotherapy: facts and hopes","volume":"27","author":"Ferrall","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"29","key":"10.1016\/j.intimp.2026.116821_bb0750","article-title":"Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma","volume":"9","author":"Ou","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"20","key":"10.1016\/j.intimp.2026.116821_bb0755","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.intimp.2026.116821_bb0760","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"First-line Pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical Cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"10421","key":"10.1016\/j.intimp.2026.116821_bb0765","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.116821_bb0770","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e116","article-title":"Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc","author":"Takekuma","year":"2025","journal-title":"J. Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0775","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0780","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001126","article-title":"Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer","volume":"8","author":"Friedman","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2026.116821_bb0785","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of Pembrolizumab in previously treated advanced cervical Cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.intimp.2026.116821_bb0790","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of Nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2026.116821_bb0795","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-19-3826","article-title":"Adenocarcinoma of the uterine cervix shows impaired recruitment of cDC1 and CD8(+) T cells and elevated \u03b2-catenin activation compared with squamous cell carcinoma","volume":"26","author":"Rotman","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.intimp.2026.116821_bb0800","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-23-3162","article-title":"Cadonilimab combined with chemotherapy with or without bevacizumab as first-line treatment in recurrent or metastatic cervical Cancer (COMPASSION-13): a phase 2 study","volume":"30","author":"Lou","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"10463","key":"10.1016\/j.intimp.2026.116821_bb0805","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2026.116821_bb0810","article-title":"Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bi-specific antibody) and adjuvant anti-angiogenesis therapy in treated, recurrent, or metastatic cervical cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0815","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116821_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104084","article-title":"Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: a systematic review and meta-analysis","volume":"189","author":"Fu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.intimp.2026.116821_bb0825","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.596825","article-title":"PD-L1 and PD-L2 expression in cervical Cancer: regulation and biomarker potential","volume":"11","author":"Rotman","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0830","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian Cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0835","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.ccell.2024.11.005","article-title":"Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer","volume":"42","author":"Launonen","year":"2024","journal-title":"Cancer Cell"},{"issue":"26","key":"10.1016\/j.intimp.2026.116821_bb0840","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0845","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/intimm\/dxaa010","article-title":"PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-\u03b3 production, but lose cytotoxic activity in ovarian cancer","volume":"32","author":"Sawada","year":"2020","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb0850","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol. Rev."},{"issue":"5706","key":"10.1016\/j.intimp.2026.116821_bb0855","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.intimp.2026.116821_bb0860","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/14796694.2024.2373680","article-title":"Efficacy and safety of VEGFR inhibitors for recurrent ovarian cancer: a systematic review","volume":"20","author":"Tan","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.intimp.2026.116821_bb0865","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2147\/OTT.S119879","article-title":"Antiangiogenic drugs used with chemotherapy for patients with recurrent ovarian cancer: a meta-analysis","volume":"10","author":"Yi","year":"2017","journal-title":"Onco. Targets Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb0870","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb0875","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1158\/1535-7163.MCT-12-0995","article-title":"BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer","volume":"12","author":"Kutluk Cenik","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"23","key":"10.1016\/j.intimp.2026.116821_bb0880","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/0008-5472.CAN-13-1989","article-title":"Benefits of vascular normalization are dose and time dependent--letter","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116821_bb0885","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.2147\/CMAR.S174712","article-title":"Monitoring of tumor vascular normalization: the key points from basic research to clinical application","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"15","key":"10.1016\/j.intimp.2026.116821_bb0890","doi-asserted-by":"crossref","first-page":"11964","DOI":"10.18632\/oncotarget.22600","article-title":"MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment","volume":"9","author":"Yang","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0895","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.molonc.2015.12.011","article-title":"Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET","volume":"10","author":"Hern\u00e1ndez-Agudo","year":"2016","journal-title":"Mol. Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116821_bb0900","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1073\/pnas.1525349113","article-title":"Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages","volume":"113","author":"Peterson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0905","first-page":"1843","article-title":"Signature of the vascular tumor microenvironment as a marker of the therapeutic response to doxorubicin in a preclinical model of osteosarcoma","volume":"12","author":"Crenn","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0910","doi-asserted-by":"crossref","first-page":"139","DOI":"10.20892\/j.issn.2095-3941.2020.0151","article-title":"VEGFR2 inhibition hampers breast cancer cell proliferation via enhanced mitochondrial biogenesis","volume":"18","author":"Ni","year":"2021","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.intimp.2026.116821_bb0915","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.isci.2018.12.015","article-title":"The phosphoinositide kinase PIKfyve promotes Cathepsin-S-mediated Major Histocompatibility Complex Class II antigen presentation","volume":"11","author":"Baranov","year":"2019","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.intimp.2026.116821_bb0920","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/msb.20134892","article-title":"Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer","volume":"10","author":"Yang","year":"2014","journal-title":"Mol. Syst. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb0925","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106020","article-title":"Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer","volume":"26","author":"Glassman","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0930","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1590\/0074-0276130252","article-title":"Vascular endothelial growth factor-a enhances indoleamine 2,3-dioxygenase expression by dendritic cells and subsequently impacts lymphocyte proliferation","volume":"109","author":"Marti","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb0935","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/onc.2016.256","article-title":"Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4","volume":"36","author":"Harjes","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116821_bb0940","doi-asserted-by":"crossref","first-page":"33","DOI":"10.22203\/eCM.v050a03","article-title":"Innovative immunomodulatory strategies in the management of peri-implantitis: current paradigms and future directions","volume":"50","author":"Wang","year":"2025","journal-title":"Eur. Cell. Mater."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0945","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41577-021-00584-1","article-title":"How the immune system shapes atherosclerosis: roles of innate and adaptive immunity","volume":"22","author":"Roy","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"18","key":"10.1016\/j.intimp.2026.116821_bb0950","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184344","article-title":"Prognostic and predictive role of tumor-infiltrating lymphocytes (TILs) in ovarian Cancer","volume":"14","author":"Fanale","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0955","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00432-019-02877-4","article-title":"Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the tumor Bank ovarian Cancer (TOC) consortium","volume":"145","author":"Guan","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116821_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2024.151459","article-title":"The expression level of VEGFR2 regulates mechanotransduction, tumor growth and metastasis of high grade serous ovarian cancer cells","volume":"103","author":"Grillo","year":"2024","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116821_bb0965","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/1471-2407-14-696","article-title":"Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer","volume":"14","author":"Sallinen","year":"2014","journal-title":"BMC Cancer"},{"issue":"17","key":"10.1016\/j.intimp.2026.116821_bb0970","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-13-3248","article-title":"The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer","volume":"20","author":"Backen","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb0975","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cjp2.184","article-title":"An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the international Endocervical adenocarcinoma criteria and classification","volume":"7","author":"Shi","year":"2021","journal-title":"J. Pathol. Clin. Res."},{"issue":"10","key":"10.1016\/j.intimp.2026.116821_bb0980","first-page":"1018","article-title":"HER2 amplification and PD-L1 expression in invasive stratified mucin-producing carcinoma of the cervix: a clinicopathological analysis of eighteen cases","volume":"53","author":"Tang","year":"2024","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"22","key":"10.1016\/j.intimp.2026.116821_bb0985","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of Dostarlimab in patients with endometrial Cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116821_bb0990","article-title":"A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116821_bb0995","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1541-7786.MCR-13-0358","article-title":"A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma","volume":"11","author":"Gyanchandani","year":"2013","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb1000","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116821_bb1005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1698088","article-title":"TGF-\u03b2-driven T-cell exclusion in ovarian cancer: single-cell and spatial transcriptomic views of immune low-response states","volume":"16","author":"He","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116821_bb1010","first-page":"129","article-title":"Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion","volume":"6","author":"H\u00e4usler","year":"2014","journal-title":"Am. J. Transl. Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb1015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1136\/ijgc-2020-001239","article-title":"\u03b2-Catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas","volume":"30","author":"Rowe","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2026.116821_bb1020","article-title":"Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma","volume":"12","author":"Ding","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.intimp.2026.116821_bb1025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cyto.2018.09.018","article-title":"Cervical cancer cells produce TGF-\u03b21 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-\u03b21","volume":"118","author":"Garc\u00eda-Rocha","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2026.116821_bb1030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1669606","article-title":"Remodeling the tumor microenvironment: regulatory effects of \u03b2-sitosterol and luteolin on the immunosuppressive milieu in endometrial carcinoma and implications for combinatorial immunotherapy","volume":"16","author":"Ji","year":"2025","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb1035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1001\/jamaoncol.2024.2145","article-title":"Bintrafusp alfa for recurrent or metastatic cervical Cancer after platinum failure: a nonrandomized controlled trial","volume":"10","author":"Birrer","year":"2024","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116821_bb1040","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85974","article-title":"TGF-\u03b2 and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies","volume":"1","author":"Courau","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.intimp.2026.116821_bb1045","article-title":"Therapeutic targeting of VEGF and\/or TGF-\u03b2 to enhance anti-PD-(L)1 therapy: the evidence from clinical trials","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"issue":"43","key":"10.1016\/j.intimp.2026.116821_bb1050","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"15","key":"10.1016\/j.intimp.2026.116821_bb1055","doi-asserted-by":"crossref","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116821_bb1060","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1073\/pnas.1018892108","article-title":"Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors","volume":"108","author":"Diop-Frimpong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.116821_bb1065","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116821_bb1070","doi-asserted-by":"crossref","first-page":"0173","DOI":"10.34133\/bmr.0173","article-title":"Nanotension relief agent enhances tissue penetration by reducing solid stress in pancreatic ductal adenocarcinoma via rho\/ROCK pathway inhibition","volume":"29","author":"Yu","year":"2025","journal-title":"Biomater Res"},{"key":"10.1016\/j.intimp.2026.116821_bb1075","doi-asserted-by":"crossref","DOI":"10.1038\/srep46140","article-title":"Tranilast-induced stress alleviation in solid tumors improves the efficacy of chemo- and nanotherapeutics in a size-independent manner","volume":"7","author":"Papageorgis","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb1080","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb1085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","article-title":"Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies","volume":"99","author":"Du","year":"2025","journal-title":"Arch. Toxicol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb1090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12882-023-03101-9","article-title":"Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report","volume":"24","author":"Liu","year":"2023","journal-title":"BMC Nephrol."},{"issue":"18","key":"10.1016\/j.intimp.2026.116821_bb1095","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1016\/j.ejca.2006.09.015","article-title":"The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review","volume":"42","author":"Eskens","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2026.116821_bb1100","first-page":"744","article-title":"Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer","volume":"9","author":"Saif","year":"2008","journal-title":"Jop"},{"key":"10.1016\/j.intimp.2026.116821_bb1105","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb1110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"1","key":"10.1016\/j.intimp.2026.116821_bb1115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926006673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:01:45Z","timestamp":1789243305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926006673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":223,"alternative-id":["S1567576926006673"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116821","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VEGF\/VEGFR targeting-induced vascular normalization: a key strategy to reverse cold tumor phenotype and potentiate immunotherapy in gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116821"}}